Drug Design of Zinc-Enzyme Inhibitors

Wiley Series in Drug Discovery and Development

Claudiu T. Supuran, Jean-Yves Winum, Binghe Wang

Drug Design of Zinc-Enzyme Inhibitors
Preview this ebook

Product details

Published22nd October 2009
ISBN9780470508152
Price£169.00
Print ISBN9780470275009
eISBN9780470508152
Authors, ,
PublisherWiley
Edition1st edition
Pages1072
LanguageEnglish
Subjects:Pharmacology
BIC:MMG
BISAC:MED071000
123Library ID:4520
Format:eBook

eBook Overview

Brings together functional and structural informationrelevant to the design of drugs targeting zinc enzymes

The second most abundant transition element in living organisms, zinc spans all areas of metabolism, with zinc-containing proteins offering both established and potential drug targets. Drug Design of Zinc-Enzyme Inhibitors brings together functional and structural information relevant to these zinc-containing targets. With up-to-date overviews of the latest developments field, this unique and comprehensive text enables readers to understand zinc enzymes and evaluate them in a drug design context.

With contributions from the leaders of today's research, Drug Design of Zinc-Enzyme Inhibitors covers such key topics as:

  • Major drug targets like carbonic anhydrases, matrix metalloproteinases, bacterial proteases, angiotensin-converting enzyme, histone deacetylase, and APOBEC3G

  • Roles of recently discovered zinc-containing isozymes in cancer, obesity, epilepsy, pain management, malaria, and other conditions

  • Cross reactivity of zinc-enzyme inhibitors and activators

  • The extensive use of X-ray crystallography and QSAR studies for understanding zinc-containing proteins

  • Clinical applications

An essential resource for the discovery and development of new drug molecules, Drug Design of Zinc-Enzyme Inhibitors gives researchers, professionals, students, and academics the foundation to understand and work with zinc enzyme inhibitors and activators.

Search inside this book:

Table of Contents

DRUG DESIGN OF ZINC-ENZYME INHIBITORS3
CONTENTS7
PREFACE11
CONTRIBUTORS13
PART I INTRODUCTION19
1. Introduction to Zinc Enzymes as Drug Targets21
PART II DRUG DESIGN OF CARBONIC ANHYDRASE INHIBITORS AND ACTIVATORS31
2. Carbonic Anhydrases as Drug Targets: General Presentation33
3. Zinc Binding Functions in the Design of Carbonic Anhydrase Inhibitors57
4. X-Ray Crystallography of Carbonic Anhydrase Inhibitors and Its Importance in Drug Design91
5. Antiglaucoma Carbonic Anhydrase Inhibitors as Ophthalomologic Drugs157
6. Diuretics with Carbonic Anhydrase Inhibitory Activity: Toward Novel Applications for Sulfonamide Drugs173
7. Drug Design of Carbonic Anhydrase Inhibitors as Anticonvulsant Agents189
8. Carbonic Anhydrase Inhibitors Targeting Cancer: Therapeutic, Immunologic, and Diagnostic Tools Targeting Isoforms IX and XII211
9. Fluorescent- and Spin-Labeled Sulfonamides as Probe for Carbonic Anhydrase IX241
10. Drug Design of Antiobesity Carbonic Anhydrase Inhibitors259
11. Dual Carbonic Anhydrase and Cyclooxygenase-2 Inhibition273
12. Advances in the Inhibitory and Structural Investigations on Carbonic Anhydrase Isozymes XIII and XV291
13. Mechanism and Inhibition of the β-Class and γ-Class Carbonic Anhydrases303
14. Fungal and Nematode Carbonic Anhydrases: Their Inhibition in Drug Design319
15. Crystallographic Studies on Carbonic Anhydrases from Fungal Pathogens for Structure-Assisted Drug Development341
16. Malaria Parasite Carbonic Anhydrase and Its Inhibition in the Development of Novel Therapies of Malaria353
17. Inhibitors of Helicobacter pylori α- and β-Carbonic Anhydrases as Novel Drugs for Gastroduodenal Diseases377
18. QSAR of Carbonic Anhydrase Inhibitors and Their Impact on Drug Design393
19. Selectivity Issues in the Design of CA Inhibitors417
20. Bicarbonate Transport Metabolons433
21. Metal Complexes of Sulfonamides as Dual Carbonic Anhydrase Inhibitors457
22. Drug Design Studies of Carbonic Anhydrase Activators491
PART III DRUG DESIGN OF MATRIX METALLOPROTEINASE INHIBITORS505
23. Matrix Metalloproteinases: An Overview507
24. MMP Inhibitors Based on Earlier Succinimide Strategies: From Early to New Approaches537
25. Drug Design of Sulfonylated MMP Inhibitors567
26. ADAMs and ADAMTs Selective Synthetic Inhibitors609
27. QSAR Studies of MMP Inhibitors665
PART IV DRUG DESIGN OF BACTERIAL ZINC PROTEASE INHIBITORS691
28. Bacterial Zinc Proteases as Orphan Targets693
29. Botulinus Toxin, Tetanus Toxin, and Anthrax Lethal Factor Inhibitors723
30. Clostridium histolyticum Collagenase Inhibitors in the Drug Design739
31. Other Bacterial Zinc Peptidases as Potential Drug Targets749
PART V DRUG DESIGN STUDIES OF OTHER ZINC-CONTAINING ENZYMES767
32. Angiotensin Converting Enzyme (ACE) Inhibitors769
33. P-III Metalloproteinase (Leucurolysin-B) from Bothrops leucurus Venom: Isolation and Possible Inhibition807
34. CaaX-Protein Prenyltransferase Inhibitors831
35. Histone Deacetylase Inhibitors877
36. Recent Development of Diagnostic and Therapeutic Agents Targeting Glutamate Carboxypeptidase II (GCPII)899
37. Targeting HIV-1 Integrase Zinc Binding Motif929
38. Inhibitors of Histidinol Dehydrogenases as Antibacterial Agents955
39. Dihydroorotase Inhibitors969
40. APOBEC3G: A Promising Antiviral Target999
Index1007